Showing results (201-210 of 259) with videos related to

Sort By:
Pageof 26
The Journal of Clinical Investigation|February 14, 1998
Substrate availability limits human skeletal muscle oxidative ATP regeneration at the onset of ischemic exerciseJ A Timmons, T Gustafsson, C J Sundberg, et al.
Nature Immunology|December 7, 2010
HLA-DM captures partially empty HLA-DR molecules for catalyzed removal of peptideAnne-Kathrin Anders, Melissa J Call, Monika-Sarah E D Schulze, et al.
Cell Reports|June 23, 2015
A Decoy Peptide that Disrupts TIRAP Recruitment to TLRs Is Protective in a Murine Model of InfluenzaWenji Piao, Kari Ann Shirey, Lisa W Ru, et al.
Cell Research|July 4, 2019
Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapyYan Zhang, Xuexiang Du, Mingyue Liu, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 1991
Characterization of posttranslational modifications in neuron-specific class III beta-tubulin by mass spectrometryJ E Alexander, D F Hunt, M K Lee, et al.
The Journal of Infectious Diseases|June 5, 2008
Neutralization of multiple staphylococcal superantigens by a single-chain protein consisting of affinity-matured, variable domain repeatsXi Yang, Rebecca A Buonpane, Beenu Moza, et al.
Biorxiv : the Preprint Server for Biology|April 16, 2025
Mapping affinity and allostery in human IgG antibody Fc region-Fc γ receptor interactionsAlasdair D Keith, Ting Xu, Tatiana A Chernova, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 5, 2006
Molecular basis of TCR selectivity, cross-reactivity, and allelic discrimination by a bacterial superantigen: integrative functional and energetic mapping of the SpeC-Vbeta2.1 molecular interfaceA K M Nur-ur Rahman, Christine A Herfst, Beenu Moza, et al.
RSC Medicinal Chemistry|November 28, 2022
The role of adjuvants in overcoming antibacterial resistance due to enzymatic drug modificationChristy El-Khoury, Elissar Mansour, Yori Yuliandra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2013
A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT TrialA Johnsson, H Hagman, J-E Frödin, et al.
Pageof 26